Clinical Trials Browser

Phase 1/2 × Immune Checkpoint Inhibitors × 30 days × Clear all

NCT06502691 2026-03-02

[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer

Phase 1/2 Recruiting

Breast Neoplasms